Grupo para la caracterización molecular de las neoplasias hematológicas
![Foto de Grupo para la caracterización molecular de las neoplasias hematológicas](/img/grupo.png)
![Foto de University of Sydney](/img/noimage_org.png)
University of Sydney
Sídney, AustraliaPublicaciones en colaboración con investigadores/as de University of Sydney (3)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
2018
-
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542